AbbVie Inc. Financing Cash Flow
AbbVie Inc. (ABBV) reported Financing Cash Flow of -$4.13 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-03
- AbbVie Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$5.05B.
- AbbVie Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $919.00M.
- AbbVie Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$4.17B.
- AbbVie Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$4.59B.
- AbbVie Inc. net cash provided by (used in) financing activities for fiscal 2025 was -$12.72B.
- AbbVie Inc. net cash provided by (used in) financing activities for fiscal 2024 was -$5.21B.
- AbbVie Inc. net cash provided by (used in) financing activities for fiscal 2023 was -$17.22B.
- AbbVie Inc. net cash provided by (used in) financing activities for fiscal 2022 was -$24.80B.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$5.05B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$4.13B 10-Q · filed 2026-08-03 | -$8.30B derived: sum of 3 quarters · filed 2026-08-03 | -$12.89B derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $919.00M 10-Q · filed 2026-05-08 | -$3.25B derived: sum of 2 quarters · filed 2026-05-08 | -$7.84B derived: sum of 3 quarters · filed 2026-05-08 | -$10.55B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | -$4.17B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$8.76B derived: sum of 2 quarters · filed 2026-02-20 | -$11.47B derived: sum of 3 quarters · filed 2026-08-03 | -$12.72B 10-K · filed 2026-02-20 |
| 2025-09-30 | -$4.59B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$7.30B derived: sum of 2 quarters · filed 2026-08-03 | -$8.56B 10-Q · filed 2025-11-04 | -$15.42B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | -$2.71B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$3.97B 10-Q · filed 2026-08-03 | -$10.83B derived: sum of 3 quarters · filed 2026-08-03 | -$13.90B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | -$1.26B 10-Q · filed 2026-05-08 | -$8.12B derived: sum of 2 quarters · filed 2026-05-08 | -$11.19B derived: sum of 3 quarters · filed 2026-05-08 | -$17.29B derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$6.86B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$9.93B derived: sum of 2 quarters · filed 2026-02-20 | -$16.03B derived: sum of 3 quarters · filed 2026-02-20 | -$5.21B 10-K · filed 2026-02-20 |
| 2024-09-30 | -$3.07B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$9.17B derived: sum of 2 quarters · filed 2025-11-04 | $1.65B 10-Q · filed 2025-11-04 | -$2.80B derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-06-30 | -$6.10B derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $4.72B 10-Q · filed 2025-08-04 | $273.00M derived: sum of 3 quarters · filed 2026-02-20 | -$2.39B derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-03-31 | $10.82B 10-Q · filed 2025-05-09 | $6.37B derived: sum of 2 quarters · filed 2026-02-20 | $3.71B derived: sum of 3 quarters · filed 2026-02-20 | -$211.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2023-12-31 | -$4.45B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$7.11B derived: sum of 2 quarters · filed 2026-02-20 | -$11.03B derived: sum of 3 quarters · filed 2026-02-20 | -$17.22B 10-K · filed 2026-02-20 |
| 2023-09-30 | -$2.66B derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | -$6.58B derived: sum of 2 quarters · filed 2024-11-04 | -$12.77B 10-Q · filed 2024-11-04 | -$22.41B derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-06-30 | -$3.92B derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$10.11B 10-Q · filed 2024-08-07 | -$19.75B derived: sum of 3 quarters · filed 2025-02-14 | -$25.26B derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-03-31 | -$6.19B 10-Q · filed 2024-05-03 | -$15.83B derived: sum of 2 quarters · filed 2025-02-14 | -$21.34B derived: sum of 3 quarters · filed 2025-02-14 | -$24.02B derived: sum of 4 quarters · filed 2025-02-14 |
| 2022-12-31 | -$9.63B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | -$15.15B derived: sum of 2 quarters · filed 2025-02-14 | -$17.83B derived: sum of 3 quarters · filed 2025-02-14 | -$24.80B 10-K · filed 2025-02-14 |
| 2022-09-30 | -$5.52B derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$8.20B derived: sum of 2 quarters · filed 2023-11-06 | -$15.17B 10-Q · filed 2023-11-06 | -$21.51B derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | -$2.68B derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$9.65B 10-Q · filed 2023-08-07 | -$15.99B derived: sum of 3 quarters · filed 2024-02-20 | -$19.63B derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | -$6.97B 10-Q · filed 2023-05-05 | -$13.31B derived: sum of 2 quarters · filed 2024-02-20 | -$16.95B derived: sum of 3 quarters · filed 2024-02-20 | -$22.84B derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | -$6.34B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | -$9.98B derived: sum of 2 quarters · filed 2024-02-20 | -$15.87B derived: sum of 3 quarters · filed 2024-02-20 | -$19.04B 10-K · filed 2024-02-20 |
| 2021-09-30 | -$3.64B derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | -$9.53B derived: sum of 2 quarters · filed 2022-11-04 | -$12.70B 10-Q · filed 2022-11-04 | -$16.40B derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-06-30 | -$5.88B derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$9.06B 10-Q · filed 2022-08-04 | -$12.75B derived: sum of 3 quarters · filed 2023-02-17 | -$15.57B derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-03-31 | -$3.17B 10-Q · filed 2022-05-06 | -$6.87B derived: sum of 2 quarters · filed 2023-02-17 | -$9.68B derived: sum of 3 quarters · filed 2023-02-17 | -$12.25B derived: sum of 4 quarters · filed 2023-02-17 |
| 2020-12-31 | -$3.69B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | -$6.51B derived: sum of 2 quarters · filed 2023-02-17 | -$9.08B derived: sum of 3 quarters · filed 2023-02-17 | -$11.50B 10-K · filed 2023-02-17 |
| 2020-09-30 | -$2.81B derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | -$5.38B derived: sum of 2 quarters · filed 2021-11-02 | -$7.81B 10-Q · filed 2021-11-02 | $18.80B derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-06-30 | -$2.57B derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-02 | -$4.99B 10-Q · filed 2021-08-02 | $21.61B derived: sum of 3 quarters · filed 2022-02-18 | $21.17B derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-03-31 | -$2.42B 10-Q · filed 2021-05-07 | $24.18B derived: sum of 2 quarters · filed 2022-02-18 | $23.74B derived: sum of 3 quarters · filed 2022-02-18 | $21.67B derived: sum of 4 quarters · filed 2022-02-18 |
| 2019-12-31 | $26.60B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $26.16B derived: sum of 2 quarters · filed 2022-02-18 | $24.09B derived: sum of 3 quarters · filed 2022-02-18 | $18.71B 10-K · filed 2022-02-18 |
| 2019-09-30 | -$441.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$2.51B derived: sum of 2 quarters · filed 2020-11-04 | -$7.89B 10-Q · filed 2020-11-04 | -$11.72B derived: sum of 4 quarters · filed 2021-02-19 |
| 2019-06-30 | -$2.07B derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | -$7.45B 10-Q · filed 2020-08-04 | -$11.28B derived: sum of 3 quarters · filed 2021-02-19 | -$10.36B derived: sum of 4 quarters · filed 2021-02-19 |
| 2019-03-31 | -$5.38B 10-Q · filed 2020-05-08 | -$9.21B derived: sum of 2 quarters · filed 2021-02-19 | -$8.29B derived: sum of 3 quarters · filed 2021-02-19 | -$17.27B derived: sum of 4 quarters · filed 2021-02-19 |
| 2018-12-31 | -$3.83B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | -$2.91B derived: sum of 2 quarters · filed 2021-02-19 | -$11.89B derived: sum of 3 quarters · filed 2021-02-19 | -$14.40B 10-K · filed 2021-02-19 |
| 2018-09-30 | $916.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$8.06B derived: sum of 2 quarters · filed 2019-11-06 | -$10.57B 10-Q · filed 2019-11-06 | -$12.50B derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-06-30 | -$8.98B derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | -$11.49B 10-Q · filed 2019-08-05 | -$13.41B derived: sum of 3 quarters · filed 2020-02-21 | -$14.22B derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-03-31 | -$2.51B 10-Q · filed 2019-05-03 | -$4.44B derived: sum of 2 quarters · filed 2020-02-21 | -$5.25B derived: sum of 3 quarters · filed 2020-02-21 | -$6.23B derived: sum of 4 quarters · filed 2020-02-21 |
| 2017-12-31 | -$1.93B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | -$2.74B derived: sum of 2 quarters · filed 2020-02-21 | -$3.72B derived: sum of 3 quarters · filed 2020-02-21 | -$5.51B 10-K · filed 2020-02-21 |
| 2017-09-30 | -$810.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$1.79B derived: sum of 2 quarters · filed 2018-11-07 | -$3.58B 10-Q · filed 2018-11-07 | -$6.09B derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-06-30 | -$980.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | -$2.77B 10-Q · filed 2018-08-07 | -$5.28B derived: sum of 3 quarters · filed 2019-02-27 | -$6.65B derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-03-31 | -$1.79B 10-Q · filed 2018-05-04 | -$4.30B derived: sum of 2 quarters · filed 2019-02-27 | -$5.67B derived: sum of 3 quarters · filed 2019-02-27 | -$4.50B derived: sum of 4 quarters · filed 2019-02-27 |
| 2016-12-31 | -$2.50B derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | -$3.87B derived: sum of 2 quarters · filed 2019-02-27 | -$2.71B derived: sum of 3 quarters · filed 2019-02-27 | -$3.93B 10-K · filed 2019-02-27 |
| 2016-09-30 | -$1.37B derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$207.00M derived: sum of 2 quarters · filed 2017-11-07 | -$1.43B 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $1.16B derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | -$55.00M 10-Q · filed 2017-08-07 | ||
| 2016-03-31 | -$1.22B 10-Q · filed 2017-05-05 | |||
| 2015-09-30 | $8.18B 10-Q · filed 2016-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |